Sorrento Therapeutics and Servier have inked a license and collaboration deal to develop, manufacture and commercialize products using Sorrento’s STI-A1110.
Tokyo-based Nichi-Iko Pharmaceutical announced that it is acquiring U.S.-based Sagent Pharmaceuticals for a total cash deal of about $736 million.
Elizabeth Holmes, the embattled CEO of blood testing company Theranos, will not be allowed to own or operate a blood testing laboratory for two years.
Following its emergence from Chapter 11 bankruptcy protection, KaloBios is in the process of reacquiring company shares owned by its disgraced former CEO.
More patients and companies are increasingly adopting mobile health solutions that have created a highly effective platform for patient engagement.
OSE Immunotherapeutics exercises option within a global license agreement with Janssen Biotech for further clinical development of FR104 in autoimmune diseases.
Two months after filing for 11 bankruptcy, Bind Therapeutics accepted a “stalking horse” bid from Pfizer.
New York-based Bristol-Myers Squibb acquired Stockholm, Sweden-based Cormorant Pharmaceuticals in a deal that could hit $520 million.
Spanish drugmaker Almirall, which is building up its business in skin treatments, could be interested in acquiring dermatology assets from Canada’s Valeant Pharmaceuticals.
KaloBios Pharmaceuticals has emerged from Chapter 11 bankruptcy and acquired the rights from Savant Neglected Diseases to develop benznidazole for treating Chagas disease.